The U.S. Food and Drug Administration (FDA) has classified a recall of over 3.1 million bottles of eye drops as a Class II recall, indicating potential temporary or reversible health risks. The recall, initiated by K.C. Pharmaceuticals, affects multiple brands sold at major retailers including Walgreens, CVS, and Kroger.
Immediate Action & Core Facts
The recall involves eight brands of over-the-counter eye drops, including Dry Eye Relief Eye Drops and Artificial Tears Sterile Lubricant Eye Drops. The FDA classified the recall as Class II, meaning the products may cause temporary or medically reversible adverse health consequences. The recall was voluntary and initiated by K.C. Pharmaceuticals after identifying a potential manufacturing issue affecting sterility.
Deeper Dive & Context
Recalled Products and Distribution
The recalled products were distributed nationwide and sold under multiple brand names. The largest lot involved over 1 million bottles of Dry Eye Relief Eye Drops. Other affected brands include Sterile Eye Drops AC, Eye Drops Advanced Relief, and Ultra Lubricating Eye Drops. The products were sold at retailers such as Rite Aid, H-E-B, Harris Teeter, and military exchanges.
FDA Classification and Risk Level
The FDA's Class II classification indicates that the products may cause temporary or medically reversible adverse health consequences. The recall was initiated due to a lack of assurance of sterility, which could not be guaranteed for the affected products. The recall numbers range from D-0409-2026 to D-0416-2026, all associated with FDA Event ID 98533.
Consumer and Retailer Response
Consumers are advised to check the FDA's report for specific lot numbers and expiration dates of the recalled products. Retailers have been instructed to remove the affected products from their shelves. The recall follows a similar incident in 2023 involving a different manufacturer whose products may have contained bacteria.
Manufacturer's Statement
K.C. Pharmaceuticals has not publicly commented on the recall, but the company voluntarily initiated the action after identifying the potential manufacturing issue. The FDA has reviewed the case and assigned the Class II classification.